Connect with us

Did You Miss These 4 Penny Stocks On Robinhood This Week?

Should You Put These On Your List Of Penny Stocks To Buy?

Published

on

This article was originally published by PennyStocks.

Are These Robinhood Penny Stocks On Your Buy Or Sell List Right Now?

As we end another week in March, both penny stocks and blue chips remain highly volatile. Overall this month has been quite bullish for many stocks under $5, yet broader markets continue trading sideways. Several factors continue to leave an impact. These include fears of long-term inflation as well as hitting short-term vaccine milestones.

On Thursday, March 18th, the NASDAQ slid down by around 3%, representing the worst day in weeks. But, natural corrections like these are common after periods of bullish interest.

In a speech given by Fed Chair Jerome Powell earlier in the week, Powell worked to curb inflation fears in the next few years. Despite this, he insisted that nothing needs to be done in the short term. Steve Sosnick, a strategist at Interactive Brokers, stated that “Chairman Powell was pretty adamant, as he had been in front of Congress as well, that he was not really inclined to do anything preemptive about inflation, but react to it if inflation becomes a problem and if we’re at full employment.”

While the bond market continues to show fears of this inflationary effect, some investors believe the market will rebound heavily in the next few months. So as businesses begin to reopen, the hopes are that bullish momentum can be the driver in the market moving forward.

Robinhood Penny Stocks Take Focus

This brings us to the growing retail population. Considered “Robinhood traders,” simply due to the surge of new retail accounts that opened on the app last year, this group has brought a new layer to the market as we know it. Millions of new accounts were opened during the pandemic showing that the “dumb money” might not be so “dumb” after all.

In fact, the huge GameStop short-squeeze that also triggered many other stocks to breakout came initially from these Robinhood traders. Understanding this dynamic, we’ll look at some of the trending penny stocks on Robinhood to watch right now. Since these are typically NYSE & Nasdaq listed companies, the liquidity is usually higher than that of OTC penny stocks. Furthermore, many more funds can buy shares of main listed names.

Penny Stocks On Robinhood To Watch: Artelo Biosciences Inc. 

Artelo Biosciences is a California-based biopharmaceutical company. It develops and produces a large range of proprietary therapeutics. This includes those that utilize the endocannabinoid system in the body. With these, it can treat multiple ailments, including anorexia, cancer, PTSD, and pain management, to name a few. Shares of ARTL stock were up on Friday after the company announced its acceptance into the Alderley Park Oncology Development Program. This program is focused on the development of the FABP5 inhibitor biomarker. 

[Read More] These Penny Stocks Have Tech Traders Looking To Buy The Dip

Dr. Andy Yates, CEO of Artelo, states that “it has recently been shown that FABP5 was detectable in saliva and breath condensate for certain tumor types, including multiple myeloma and lung cancer, suggesting that these readily available and non-invasive biofluids could be used to measure FABP5 expression as a predictive biomarker of both disease prognosis and also response to FABP5 inhibition in cancers with high unmet need.” 

With this acceptance, the company could receive up to $8 million in U.S. Government financial support. Also, it will allow it to collaborate with leading UK research institutes. This is exciting news and could continue to become more exciting as time goes on. With its other work on CBD Cocrystals and its sizable pipeline, Artelo continues to offer an interesting angle on the cannabis industry.

Penny Stocks to Watch Artelo Biosciences Inc ARTL Stock Chart

Centennial Resource Development Inc. 

After announcing a $150 million senior note offering, shares of CDEV have since been climbing. For some context, Centennial Resource Development is an independent natural gas and oil company working on developing its large resource bank. It is focused on several reserves located in the Permian Basin, an extremely energy-rich area in the U.S.

With exposure to the U.S. energy market, CDEV has seen a correlative bullish interest in the past few months. The analyst firm Piper Sandler gave a neutral rating to CDEV but upgraded its price target to $5.50 per share. While investors consider it a smaller energy company with a market cap north of $1.5 billion, the company is seeing a boost in value due to the declining number of Covid cases.

With fewer cases reported, more people are traveling in cars, planes and other methods of transport. You’ve also got to consider the uptick in manufacturing that requires fuel sources as well. This means that the energy demand could continue to climb into the near future.

In its most recent fourth quarter, CDEV reported revenue of around $148 million. This is basically the same as the quarter prior. What’s more interesting is that the average realized oil price it received during the quarter jumped from $36.95 in Q3 to $40.36 in this fourth quarter. This is a solid gain and is something for investors to take note of. With a $40 million non-cash impairment expense during the quarter, CDEV reported a GAAP net loss of $89 million.

Penny Stocks to Watch Centennial Resource Development Inc CDEV Stock

Marker Therapeutics Inc. 

Another biotech penny stock on the radar is Marker Therapeutics Inc. Marker, a clinical-stage immune-oncology company, specializes in T-cell-based immunotherapies. These compounds have implications for the treatment of hematological malignancies as well as solid tumors.

Earlier in the week, Marker announced a public offering of over 32.2 million shares of common stock. The company expects to bring in roughly $56.5 million from this offering. Only a week or so earlier, MRKR reported its fiscal year 2020 operating and financial results. To understand Marker better, let’s take a look at the report. 

Peter Hoang, CEO of Marker Therapeutics, stated that “we are proud of our Company’s continued progress, which has positioned us for a busy and productive year ahead. Recently, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia or AML.”

[Read More] Best Penny Stocks To Buy This Week? These 4 Tech Stocks Are Hot

Financially, Marker ended the quarter with cash on hand of $21.4 million. While it did report a net loss of $28.7 million, this is quite common amongst biotech firms. The dosing of its first patient in the Phase 2 trial of MT-401 signals a large step forward for the company. It states that it could improve the survival rate of a potentially broad range of cancers. It plans to enroll a total of 160 patients across around 20 cancer centers in the U.S. While this will take some time to complete, in the meantime, this is definitely exciting news.

Penny Stocks to Watch Marker Therapeutics Inc MRKR Stock Chart

Akebia Therapeutics Inc. 

As far as biotech penny stocks go, Akebia Therapeutics remains quite popular. It is a fully integrated biopharmaceutical company with a heavy focus on the treatment of kidney disease. Only a few weeks ago, the company announced its fourth-quarter and full-year financial results. It also announced a $60 million non-dilutive transaction to monetize its royalties with the vadadustat compound.

CEO John Butler stated that “2020 was a year of focused execution for Akebia as we advanced vadadustat, our investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor or HIF-PHI, and executed on our commercial priorities. Importantly, we achieved this while continuing to provide patients with access to our therapies and keeping with our goal of maintaining a strong balance sheet.” 

Financially, Akebia brought in $56.7 million in revenue for the fourth quarter alone. For the full year, this number jumps to $295 million. This is lower than the previous year, but the company attributes this to lower collaboration revenue while it focuses on the development of vadadustat. During the fourth quarter, Akebia recorded a net loss of $87 million.

This is sizably less than the $94.5 million in Q4 2019. Despite this large loss, Akebia still managed to end the year with more than $268 million in cash on hand. While the pandemic has affected Akebia, it seems as though the company is still growing despite this. With its advantage cash position, is AKBA a penny stock to watch?

Penny Stocks to Watch Akebia Therapeutics Inc AKBA Stock Chart

The post 4 Penny Stocks On Robinhood You Might’ve Missed This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Uncategorized

Key shipping company files Chapter 11 bankruptcy

The Illinois-based general freight trucking company filed for Chapter 11 bankruptcy to reorganize.

Published

on

The U.S. trucking industry has had a difficult beginning of the year for 2024 with several logistics companies filing for bankruptcy to seek either a Chapter 7 liquidation or Chapter 11 reorganization.

The Covid-19 pandemic caused a lot of supply chain issues for logistics companies and also created a shortage of truck drivers as many left the business for other occupations. Shipping companies, in the meantime, have had extreme difficulty recruiting new drivers for thousands of unfilled jobs.

Related: Tesla rival’s filing reveals Chapter 11 bankruptcy is possible

Freight forwarder company Boateng Logistics joined a growing list of shipping companies that permanently shuttered their businesses as the firm on Feb. 22 filed for Chapter 7 bankruptcy with plans to liquidate.

The Carlsbad, Calif., logistics company filed its petition in the U.S. Bankruptcy Court for the Southern District of California listing assets up to $50,000 and and $1 million to $10 million in liabilities. Court papers said it owed millions of dollars in liabilities to trucking, logistics and factoring companies. The company filed bankruptcy before any creditors could take legal action.

Lawsuits force companies to liquidate in bankruptcy

Lawsuits, however, can force companies to file bankruptcy, which was the case for J.J. & Sons Logistics of Clint, Texas, which on Jan. 22 filed for Chapter 7 liquidation in the U.S. Bankruptcy Court for the Western District of Texas. The company filed bankruptcy four days before the scheduled start of a trial for a wrongful death lawsuit filed by the family of a former company truck driver who had died from drowning in 2016.

California-based logistics company Wise Choice Trans Corp. shut down operations and filed for Chapter 7 liquidation on Jan. 4 in the U.S. Bankruptcy Court for the Northern District of California, listing $1 million to $10 million in assets and liabilities.

The Hayward, Calif., third-party logistics company, founded in 2009, provided final mile, less-than-truckload and full truckload services, as well as warehouse and fulfillment services in the San Francisco Bay Area.

The Chapter 7 filing also implemented an automatic stay against all legal proceedings, as the company listed its involvement in four legal actions that were ongoing or concluded. Court papers reportedly did not list amounts for damages.

In some cases, debtors don't have to take a drastic action, such as a liquidation, and can instead file a Chapter 11 reorganization.

Truck shipping products.

Shutterstock

Nationwide Cargo seeks to reorganize its business

Nationwide Cargo Inc., a general freight trucking company that also hauls fresh produce and meat, filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Northern District of Illinois with plans to reorganize its business.

The East Dundee, Ill., shipping company listed $1 million to $10 million in assets and $10 million to $50 million in liabilities in its petition and said funds will not be available to pay unsecured creditors. The company operates with 183 trucks and 171 drivers, FreightWaves reported.

Nationwide Cargo's three largest secured creditors in the petition were Equify Financial LLC (owed about $3.5 million,) Commercial Credit Group (owed about $1.8 million) and Continental Bank NA (owed about $676,000.)

The shipping company reported gross revenue of about $34 million in 2022 and about $40 million in 2023.  From Jan. 1 until its petition date, the company generated $9.3 million in gross revenue.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

Uncategorized

Tight inventory and frustrated buyers challenge agents in Virginia

With inventory a little more than half of what it was pre-pandemic, agents are struggling to find homes for clients in Virginia.

Published

on

No matter where you are in the state, real estate agents in Virginia are facing low inventory conditions that are creating frustrating scenarios for their buyers.

“I think people are getting used to the interest rates where they are now, but there is just a huge lack of inventory,” said Chelsea Newcomb, a RE/MAX Realty Specialists agent based in Charlottesville. “I have buyers that are looking, but to find a house that you love enough to pay a high price for — and to be at over a 6.5% interest rate — it’s just a little bit harder to find something.”

Newcomb said that interest rates and higher prices, which have risen by more than $100,000 since March 2020, according to data from Altos Research, have caused her clients to be pickier when selecting a home.

“When rates and prices were lower, people were more willing to compromise,” Newcomb said.

Out in Wise, Virginia, near the westernmost tip of the state, RE/MAX Cavaliers agent Brett Tiller and his clients are also struggling to find suitable properties.

“The thing that really stands out, especially compared to two years ago, is the lack of quality listings,” Tiller said. “The slightly more upscale single-family listings for move-up buyers with children looking for their forever home just aren’t coming on the market right now, and demand is still very high.”

Statewide, Virginia had a 90-day average of 8,068 active single-family listings as of March 8, 2024, down from 14,471 single-family listings in early March 2020 at the onset of the COVID-19 pandemic, according to Altos Research. That represents a decrease of 44%.

Virginia-Inventory-Line-Chart-Virginia-90-day-Single-Family

In Newcomb’s base metro area of Charlottesville, there were an average of only 277 active single-family listings during the same recent 90-day period, compared to 892 at the onset of the pandemic. In Wise County, there were only 56 listings.

Due to the demand from move-up buyers in Tiller’s area, the average days on market for homes with a median price of roughly $190,000 was just 17 days as of early March 2024.

“For the right home, which is rare to find right now, we are still seeing multiple offers,” Tiller said. “The demand is the same right now as it was during the heart of the pandemic.”

According to Tiller, the tight inventory has caused homebuyers to spend up to six months searching for their new property, roughly double the time it took prior to the pandemic.

For Matt Salway in the Virginia Beach metro area, the tight inventory conditions are creating a rather hot market.

“Depending on where you are in the area, your listing could have 15 offers in two days,” the agent for Iron Valley Real Estate Hampton Roads | Virginia Beach said. “It has been crazy competition for most of Virginia Beach, and Norfolk is pretty hot too, especially for anything under $400,000.”

According to Altos Research, the Virginia Beach-Norfolk-Newport News housing market had a seven-day average Market Action Index score of 52.44 as of March 14, making it the seventh hottest housing market in the country. Altos considers any Market Action Index score above 30 to be indicative of a seller’s market.

Virginia-Beach-Metro-Area-Market-Action-Index-Line-Chart-Virginia-Beach-Norfolk-Newport-News-VA-NC-90-day-Single-Family

Further up the coastline on the vacation destination of Chincoteague Island, Long & Foster agent Meghan O. Clarkson is also seeing a decent amount of competition despite higher prices and interest rates.

“People are taking their time to actually come see things now instead of buying site unseen, and occasionally we see some seller concessions, but the traffic and the demand is still there; you might just work a little longer with people because we don’t have anything for sale,” Clarkson said.

“I’m busy and constantly have appointments, but the underlying frenzy from the height of the pandemic has gone away, but I think it is because we have just gotten used to it.”

While much of the demand that Clarkson’s market faces is for vacation homes and from retirees looking for a scenic spot to retire, a large portion of the demand in Salway’s market comes from military personnel and civilians working under government contracts.

“We have over a dozen military bases here, plus a bunch of shipyards, so the closer you get to all of those bases, the easier it is to sell a home and the faster the sale happens,” Salway said.

Due to this, Salway said that existing-home inventory typically does not come on the market unless an employment contract ends or the owner is reassigned to a different base, which is currently contributing to the tight inventory situation in his market.

Things are a bit different for Tiller and Newcomb, who are seeing a decent number of buyers from other, more expensive parts of the state.

“One of the crazy things about Louisa and Goochland, which are kind of like suburbs on the western side of Richmond, is that they are growing like crazy,” Newcomb said. “A lot of people are coming in from Northern Virginia because they can work remotely now.”

With a Market Action Index score of 50, it is easy to see why people are leaving the Washington-Arlington-Alexandria market for the Charlottesville market, which has an index score of 41.

In addition, the 90-day average median list price in Charlottesville is $585,000 compared to $729,900 in the D.C. area, which Newcomb said is also luring many Virginia homebuyers to move further south.

Median-Price-D.C.-vs.-Charlottesville-Line-Chart-90-day-Single-Family

“They are very accustomed to higher prices, so they are super impressed with the prices we offer here in the central Virginia area,” Newcomb said.

For local buyers, Newcomb said this means they are frequently being outbid or outpriced.

“A couple who is local to the area and has been here their whole life, they are just now starting to get their mind wrapped around the fact that you can’t get a house for $200,000 anymore,” Newcomb said.

As the year heads closer to spring, triggering the start of the prime homebuying season, agents in Virginia feel optimistic about the market.

“We are seeing seasonal trends like we did up through 2019,” Clarkson said. “The market kind of soft launched around President’s Day and it is still building, but I expect it to pick right back up and be in full swing by Easter like it always used to.”

But while they are confident in demand, questions still remain about whether there will be enough inventory to support even more homebuyers entering the market.

“I have a lot of buyers starting to come off the sidelines, but in my office, I also have a lot of people who are going to list their house in the next two to three weeks now that the weather is starting to break,” Newcomb said. “I think we are going to have a good spring and summer.”

Read More

Continue Reading

International

‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

‘Excess Mortality Skyrocketed’: Tucker Carlson and Dr. Pierre Kory Unpack ‘Criminal’ COVID Response

As the global pandemic unfolded, government-funded…

Published

on

'Excess Mortality Skyrocketed': Tucker Carlson and Dr. Pierre Kory Unpack 'Criminal' COVID Response

As the global pandemic unfolded, government-funded experimental vaccines were hastily developed for a virus which primarily killed the old and fat (and those with other obvious comorbidities), and an aggressive, global campaign to coerce billions into injecting them ensued.

Then there were the lockdowns - with some countries (New Zealand, for example) building internment camps for those who tested positive for Covid-19, and others such as China welding entire apartment buildings shut to trap people inside.

It was an egregious and unnecessary response to a virus that, while highly virulent, was survivable by the vast majority of the general population.

Oh, and the vaccines, which governments are still pushing, didn't work as advertised to the point where health officials changed the definition of "vaccine" multiple times.

Tucker Carlson recently sat down with Dr. Pierre Kory, a critical care specialist and vocal critic of vaccines. The two had a wide-ranging discussion, which included vaccine safety and efficacy, excess mortality, demographic impacts of the virus, big pharma, and the professional price Kory has paid for speaking out.

Keep reading below, or if you have roughly 50 minutes, watch it in its entirety for free on X:

"Do we have any real sense of what the cost, the physical cost to the country and world has been of those vaccines?" Carlson asked, kicking off the interview.

"I do think we have some understanding of the cost. I mean, I think, you know, you're aware of the work of of Ed Dowd, who's put together a team and looked, analytically at a lot of the epidemiologic data," Kory replied. "I mean, time with that vaccination rollout is when all of the numbers started going sideways, the excess mortality started to skyrocket."

When asked "what kind of death toll are we looking at?", Kory responded "...in 2023 alone, in the first nine months, we had what's called an excess mortality of 158,000 Americans," adding "But this is in 2023. I mean, we've  had Omicron now for two years, which is a mild variant. Not that many go to the hospital."

'Safe and Effective'

Tucker also asked Kory why the people who claimed the vaccine were "safe and effective" aren't being held criminally liable for abetting the "killing of all these Americans," to which Kory replied: "It’s my kind of belief, looking back, that [safe and effective] was a predetermined conclusion. There was no data to support that, but it was agreed upon that it would be presented as safe and effective."

Carlson and Kory then discussed the different segments of the population that experienced vaccine side effects, with Kory noting an "explosion in dying in the youngest and healthiest sectors of society," adding "And why did the employed fare far worse than those that weren't? And this particularly white collar, white collar, more than gray collar, more than blue collar."

Kory also said that Big Pharma is 'terrified' of Vitamin D because it "threatens the disease model." As journalist The Vigilant Fox notes on X, "Vitamin D showed about a 60% effectiveness against the incidence of COVID-19 in randomized control trials," and "showed about 40-50% effectiveness in reducing the incidence of COVID-19 in observational studies."

Professional costs

Kory - while risking professional suicide by speaking out, has undoubtedly helped save countless lives by advocating for alternate treatments such as Ivermectin.

Kory shared his own experiences of job loss and censorship, highlighting the challenges of advocating for a more nuanced understanding of vaccine safety in an environment often resistant to dissenting voices.

"I wrote a book called The War on Ivermectin and the the genesis of that book," he said, adding "Not only is my expertise on Ivermectin and my vast clinical experience, but and I tell the story before, but I got an email, during this journey from a guy named William B Grant, who's a professor out in California, and he wrote to me this email just one day, my life was going totally sideways because our protocols focused on Ivermectin. I was using a lot in my practice, as were tens of thousands of doctors around the world, to really good benefits. And I was getting attacked, hit jobs in the media, and he wrote me this email on and he said, Dear Dr. Kory, what they're doing to Ivermectin, they've been doing to vitamin D for decades..."

"And it's got five tactics. And these are the five tactics that all industries employ when science emerges, that's inconvenient to their interests. And so I'm just going to give you an example. Ivermectin science was extremely inconvenient to the interests of the pharmaceutical industrial complex. I mean, it threatened the vaccine campaign. It threatened vaccine hesitancy, which was public enemy number one. We know that, that everything, all the propaganda censorship was literally going after something called vaccine hesitancy."

Money makes the world go 'round

Carlson then hit on perhaps the most devious aspect of the relationship between drug companies and the medical establishment, and how special interests completely taint science to the point where public distrust of institutions has spiked in recent years.

"I think all of it starts at the level the medical journals," said Kory. "Because once you have something established in the medical journals as a, let's say, a proven fact or a generally accepted consensus, consensus comes out of the journals."

"I have dozens of rejection letters from investigators around the world who did good trials on ivermectin, tried to publish it. No thank you, no thank you, no thank you. And then the ones that do get in all purportedly prove that ivermectin didn't work," Kory continued.

"So and then when you look at the ones that actually got in and this is where like probably my biggest estrangement and why I don't recognize science and don't trust it anymore, is the trials that flew to publication in the top journals in the world were so brazenly manipulated and corrupted in the design and conduct in, many of us wrote about it. But they flew to publication, and then every time they were published, you saw these huge PR campaigns in the media. New York Times, Boston Globe, L.A. times, ivermectin doesn't work. Latest high quality, rigorous study says. I'm sitting here in my office watching these lies just ripple throughout the media sphere based on fraudulent studies published in the top journals. And that's that's that has changed. Now that's why I say I'm estranged and I don't know what to trust anymore."

Vaccine Injuries

Carlson asked Kory about his clinical experience with vaccine injuries.

"So how this is how I divide, this is just kind of my perception of vaccine injury is that when I use the term vaccine injury, I'm usually referring to what I call a single organ problem, like pericarditis, myocarditis, stroke, something like that. An autoimmune disease," he replied.

"What I specialize in my practice, is I treat patients with what we call a long Covid long vaxx. It's the same disease, just different triggers, right? One is triggered by Covid, the other one is triggered by the spike protein from the vaccine. Much more common is long vax. The only real differences between the two conditions is that the vaccinated are, on average, sicker and more disabled than the long Covids, with some pretty prominent exceptions to that."

Watch the entire interview above, and you can support Tucker Carlson's endeavors by joining the Tucker Carlson Network here...

Tyler Durden Thu, 03/14/2024 - 16:20

Read More

Continue Reading

Trending